Single-Dose Sputnik Light Vaccine Found Effective with Seniors
EClinicalMedicine, an open-access peer-reviewed clinical journal published by The Lancet, found the Sputnik Light vaccine effectively prevented disease among 415,000 seniors living in the Province of Buenos Aires in Argentina.
According to this observational study published on September 12, 2021, the single component of the Sputnik Light vaccine has demonstrated 78.6-83.7% general efficacy against COVID-19 in subjects aged 60-79 years old.
Furthermore, Sputnik Light demonstrated efficacy against hospitalizations at 82.1-87.6%.
These researchers concluded by saying, 'Similarly to other COVID-19 vaccines, the administration of one dose of Sputnik Light (Gam-COVID-Vac) was effective for a wide range of COVID-19–related outcomes.'
Sputnik Light is a recombinant human adenovirus 26 serotype (rAd26) vaccine based on a well-studied platform of human adenoviral vectors, which cause the common cold. As of September 14, 2021, the Sputnik Light vaccine is available in over (18) countries:
Note: This study did not receive outside funding, and the researchers did not disclose any industry conflicts of interest.
The first limitation of this study lies in the observational nature of the study design. In addition, cohort studies differ from clinical trials in several aspects; as the unvaccinated population does not receive a placebo, any behavioral change in the vaccinated population, such as modifying prevention measures and social distancing, might be a source of systematic uncertainty.